3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Blood Specimen Collection
15
Imatinib Mesylate
10
Flow Cytometry
10
nilotinib
8
Surveys and Questionnaires
8
Polymerase Chain Reaction
8
ponatinib
6
Cytogenetic Analysis
6
ruxolitinib
5
bosutinib
5
Psychiatric Rehabilitation
5
Dasatinib
5
Therapeutics
4
Interviews as Topic
4
Biopsy
4
asciminib
3
Observation
3
Microarray Analysis
3
In Situ Hybridization, Fluorescence
3
Immunoenzyme Techniques
3
Amplified Fragment Length Polymorphism Analysis
3
olverembatinib
2
fludarabine
2
Watchful Waiting
2
Tyrosine Kinase Inhibitors
2
Molecular Diagnostic Techniques
2
Influenza Vaccines
2
Immunologic Techniques
2
Immunohistochemistry
2
Hydroxyurea
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Tinzaparin
×
Myeloid
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled